In the first action taken since its initial look into the so-called pay-for-delay agreements of the pharmaceutical sector, the European Commission will reportedly fine a generic drug manufacturer in a move that suggests the regulator is ready to fight what it considers an anticompetitive, consumer-harming practice. Lundbeck, based in Denmark, as well as eight other generic drug makers will be fined by the Commission for entering into the agreements, which the Commission found to have blocked access to cheaper drugs for consumers. Since the probe was first launched into the sector in 2009, the Commission has determined that consumers could be hit with up to 20 percent markups for brand name prescription drugs. Both the US and the European Union are looking to clamp down on the anticompetitive practice. Reports say the EU will announce the fines later this month, according to Commission officials.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google Faces DOJ Antitrust Trial, Publishers Watch Closely for Impact on Ad Market
Sep 9, 2024 by
CPI
India Moves to Challenge Big Tech Power in Digital Markets
Sep 9, 2024 by
CPI
US Tightens Grip on AI: New Reporting Rules for Developers and Cloud Providers
Sep 9, 2024 by
CPI
EU Court to Decide Apple’s €13bn Tax Battle
Sep 9, 2024 by
CPI
Google Lawyer Kevin Yingling Joins Freshfields Amid Antitrust Fight
Sep 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI